The drug diffusion barriers and efflux pumps present in the tumor microenvironment (Fig. 3) can significantly diminish the availability of TMEM16A inhibitors, highlighting the necessity for optimized delivery systems for clinical application [5, 62]. Here, ANO1 is linked to neoplasm.